[
    [
        {
            "time": "2023-10-15",
            "original_text": "Novartis' (NVS) COVID-19 Study Fails to Meet Primary Endpoint",
            "features": {
                "keywords": [
                    "Novartis",
                    "COVID-19",
                    "Study",
                    "Fails",
                    "Primary",
                    "Endpoint"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "20 Biggest Healthcare Companies By Revenue",
            "features": {
                "keywords": [
                    "Biggest",
                    "Healthcare",
                    "Companies",
                    "Revenue"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 2,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema",
            "features": {
                "keywords": [
                    "Novartis",
                    "positive",
                    "topline",
                    "results",
                    "Phase",
                    "III",
                    "trial",
                    "Beovu®",
                    "diabetic",
                    "macular",
                    "edema"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]